High Throughput Screening 시장 예측(-2030년)

Market Overview

High Throughput Screening Market is anticipated to register a significant CAGR of 9.70% during the forecast period.

The variables adding to the development of the market are the developing genomic research exercises, rising interest for customized medication, expanding interest in innovative work, and expanding mindfulness and reception.

The high-throughput screening market is encountering significant development because of the rising interest for customized medication. Customized medication, otherwise called accuracy medication, is an inventive methodology that thinks about a singular's exceptional hereditary cosmetics, way of life, and natural variables to tailor clinical medicines and mediations. High-throughput screening, with its capacity to succession enormous volumes of DNA or RNA quickly and cost-really, assumes a crucial part in the headway of customized medication. One of the essential drivers behind the rising interest for customized medication is the developing acknowledgment that people answer diversely to medicines because of their one-of-a-kind hereditary variety. High-throughput screening empowers the ID of sickness related hereditary variations and offers bits of knowledge into the hereditary variables fundamental the viability and security of explicit treatments. By breaking down a person's hereditary data, medical care experts can decide the most appropriate therapy choices and upgrade measurements, bringing about superior patient results.

Market Segment Insights

Based on product & service, the High Throughput Screening Market has been segmented into consumables, instruments, and software & services. Based on technology, the Market has classified into cell-based assays, Lab-on-a-Chip (LOC), ultra-high-throughput screening, label-free technology, and others.

Based on application, the High Throughput Screening Market has segmented into drug discovery, biochemical screening, cell & organ-based screening, and others. In terms of end user, the Market has categorized into pharmaceutical and biotechnology companies, research institutes and organizations, and contract research organizations.

Regional Insights

North America represented the biggest market portion of 42.96% in 2022 and Asia-Pacific is projected to develop at the highest CAGR of 11.01% during the figure time frame. Moreover, market development is driven by expanding clinical preliminary numbers across the globe, and developing exploration and improvement. In addition, the underneath diagram addresses the quantity of clinical preliminaries for every region began in 2022. The market development has been driven by inorganic procedures to extend high-throughput screening (HTS) answers for measure biochemical exercises and recognize restricting associations, which speed up the timetable and lessen expenses to distinguish lead drug competitors. For example, in January 2023, Charles Waterway Research Facilities Global, Inc. (US) procured SAMDI Tech, Inc. (US), a main supplier of HTS answers for grow HTS portfolio.

The development of the European high-throughput screening market is driven by elevating HTS undertakings to speed up the revelation of a lead particle for another medication. For example, in Walk 2023, SCREENTECH opened under the correlative arrangement for biotechnology in Catalonia (Spain). This drive focused on the advancement of new ventures in view of the medication screening and medication target connection examination stage at IRB Barcelona (US).

In addition, the high guilty pleasure of high-throughput screening fire up designers like CN Bio (UK), Evosep (Denmark), Ovizio (Belgium), and Oxford Nanopore Advancements plc. (UK) through raising financing and consolidating advancement is setting out enormous open doors for the region's development.

Major Players

Key Companies in the High Throughput Screening Market are Agilent Technologies Inc, Merck KGaA, Corning Incorporated, Tecan Trading AG, PerkinElmer Inc, Luminex Corporation, Beckman Coulter Inc, Hoffmann-La Roche Ltd, Promega Corporation, Hamilton Company, and Others.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 GROWING GENOMIC RESEARCH ACTIVITIES
  • 4.2.2 RISING DEMAND FOR PERSONALIZED MEDICINE
  • 4.2.3 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
• 4.3 RESTRAINTS
  • 4.3.1 HIGH INITIAL SETUP COSTS
• 4.4 OPPORTUNITY
  • 4.4.1 INCREASING AWARENESS AND ADOPTION

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D & DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE GLOBAL HIGH THROUGHPUT SCREENING MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON PRODUCTION
  • 5.3.3 IMPACT ON REGION
  • 5.3.4 IMPACT ON PRICING

6 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY PRODUCTS & SERVICES

• 6.1 OVERVIEW
• 6.2 CONSUMABLES
• 6.3 INSTRUMENTS
• 6.4 SOFTWARE & SERVICES

7 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY TECHNOLOGY

• 7.1 OVERVIEW
• 7.2 CELL-BASED ASSAYS
  • 7.2.1D CELL CULTURE
• 7.3 LAB-ON-A-CHIP (LOC)
• 7.4 ULTRA-HIGH-THROUGHPUT SCREENING
• 7.5 LABEL-FREE TECHNOLOGY
• 7.6 OTHERS

8 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 DRUG DISCOVERY
• 8.3 BIOCHEMICAL SCREENING
• 8.4 CELL- & ORGAN-BASED SCREENING
• 8.5 OTHERS

9 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY END USER

• 9.1 OVERVIEW
• 9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
• 9.3 RESEARCH INSTITUTES AND ORGANISATIONS
• 9.4 CONTRACT RESEARCH ORGANIZATIONS

10 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 GERMANY
  • 10.3.2 FRANCE
  • 10.3.3 UK
  • 10.3.4 ITALY
  • 10.3.5 SPAIN
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA-PACIFIC
  • 10.4.1 CHINA
  • 10.4.2 JAPAN
  • 10.4.3 INDIA
  • 10.4.4 SOUTH KOREA
  • 10.4.5 AUSTRALIA
  • 10.4.6 REST OF ASIA-PACIFIC
• 10.5 REST OF THE WORLD
  • 10.5.1 MIDDLE EAST
  • 10.5.2 AFRICA
  • 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 COMPETITIVE BENCHMARKING
• 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HIGH THROUGHPUT SCREENING MARKET
• 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL HIGH THROUGHPUT SCREENING MARKET
• 11.5 KEY DEVELOPMENT ANALYSIS
• 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.6.1 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL
  • 11.6.2 COLLABORATION/AGREEMENT
  • 11.6.3 ACQUISITION/MERGER
• 11.7 FINANCIAL MATRIX
  • 11.7.1 SALES (USD MILLION),
  • 11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION),

12 COMPANY PROFILES

• 12.1 CORNING INCORPORATED
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL OVERVIEW
  • 12.1.3 PRODUCTS OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 SWOT ANALYSIS
  • 12.1.6 KEY STRATEGIES
• 12.2 AGILENT TECHNOLOGIES, INC
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 PRODUCTS OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 KEY STRATEGIES
• 12.3 LUMINEX CORPORATION
  • 12.3.1 COMPANY OVERVIEWS
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 PRODUCTS OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 KEY STRATEGIES
• 12.4 F. HOFFMANN-LA ROCHE LTD
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 SWOT ANALYSIS
  • 12.4.6 KEY STRATEGIES
• 12.5 PROMEGA CORPORATION
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 KEY STRATEGIES
• 12.6 MERCK KGAA
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 SWOT ANALYSIS
  • 12.6.6 KEY STRATEGIES
• 12.7 TECAN TRADING AG
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 PERKINELMER INC
  • 12.8.1 COMPANY OVERVIEWS
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 KEY STRATEGIES
• 12.9 BECKMAN COULTER, INC
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 SWOT ANALYSIS
  • 12.9.6 KEY STRATEGIES
• 12.10 HAMILTON COMPANY
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 KEY STRATEGIES

13 APPENDIX

• 13.1 REFERENCES
• 13.2 RELATED REPORTS